Drug Profile

QR 1123

Alternative Names: ION-357; IONIS-RHO-2.5Rx; ISIS-GSK5-2.5Rx; ISIS-GSK5Rx; ISIS-RHO-2.5Rx; QR-1123

Latest Information Update: 11 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ionis Pharmaceuticals
Class Antisense oligonucleotides; Eye disorder therapies
Mechanism of Action Rhodopsin expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinitis pigmentosa
New Molecular Entity Yes

Highest Development Phases

Suspended Retinitis pigmentosa

Most Recent Events

31 Jan 2024 ProQR terminates its licence for QR in 1123
30 Apr 2022 Suspended - Phase-II for Retinitis pigmentosa in USA (Intravitreous)
18 Nov 2021 Adverse events and efficacy data from the phase I/II Aurora trial in Retinitis pigmentosa released by ProQR

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com